NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

But then she changes that observation to indicate that IDH1 wild-type is actually present in both populations. I thought that was worth noting - that it was found in both MGMT plus and minus. I do wonder how many of that group of 100 longer living survivors from the interim data with a mOS of 40.5 months will turn out to be IDH1 wild-type.

Hi Senti. It's generally thought that about 90% of GBM's are wildtype, and that rises to nearly 100% of primary GBM's.

IDH mutation goes together with secondary glioblastoma and proneural signature, and is usually frontal lobe.

Clearly, IDH wild type is found in both meth and unmeth.

IDH mutation is linked with younger age at diagnosis, and is a favorable prognostic. Maybe 3-fold survival time.

i don't know where that leaves us with mesenchymal though.
I have this uncomfortable feeling that LL et al, have been barking up the wrong tree for the last 5 or 6 years....

It raises the possibility that one or both of Kat and Jeanine were IDH-mutated, neither having had a primary GBM.

As we know, IDH status was not tested (at least prospectively) for this trial.


https://academic.oup.com/neurosurgery/article/64/CN_suppl_1/134/4093190